Cost effectiveness of 5-Alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations

PharmacoEconomics

Volumn 28, Issue 6, 2010, Pages 489-505

  Earnshaw, Stephanie R ^a   McDade, Cheryl L ^a   Black, Libby K ^b   Bell, Christopher F ^b   Kattan, Michael W ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

5 alpha reductase inhibitors; Cost utility; Prevention; Prostate cancer; Therapeutic use

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION MAKING; DIGITAL RECTAL EXAMINATION; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FAMILY HISTORY; FECES INCONTINENCE; HEALTH STATUS; HIGH RISK POPULATION; HUMAN; IMPOTENCE; LIBIDO DISORDER; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT OUTCOME; URINE INCONTINENCE; URINE RETENTION; VALIDATION STUDY;

AGE FACTORS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ENZYME INHIBITORS; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; POPULATION GROUPS; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 77952556815     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11531780-000000000-00000     Document Type: Article

References (58)

1. Parnes HL, Thompson IM, Ford LG. Prevention of hormone-related cancers: Prostate cancer. J Clin Oncol 2005;23(2):(368)-77
2. National Cancer Institute. Common cancer types [online]. Available from URL: Http://Www.cancer.gov/cancertopics/commoncancers [Accessed 2009 Jun. 24]
3. American Cancer Society. Cancer facts and figures 2009. Atlanta (GA): American Cancer Society, 2009
4. Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004;63(4):(709)-15
5. Thompson IM, Goodman PH, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):(213)-22
6. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 60:434-41
7. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998 338:557-63
8. Andriole G, Bostwick D, Brawley O, et al., for the REDUCE Study Group. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172(4 Pt 1):1314-7
9. Jack A. Cancer drug boost for Glaxo. Financial Times 2009 Apr. 28 [online]. Available from URL: Http://Www.ft.com/cms/s/0/cf252cf6-337f-11de-8f1b- 00144feabdc0.html?nclick-check=1 [Accessed 2009 Jun. 15]
10. Zeliadt SB, Etzioni RD, Penson DF, et al. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 2005 118:850-7
11. Svatek RS, Lee JJ, Roehrborn CG, et al. The cost of prostate cancer chemoprevention: A decision analysis model. Cancer Epidemiol Biomarkers Prev 2006;15(8):(1485)-9
12. Svatek RS, Lee JJ, Roehrborn CG, et al. Cost-effectiveness of prostate cancer chemoprevention: A quality of life-years analysis. Cancer 2008;112(5):(1058)-65
13. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005 23:7005-12
14. Weinstein MC. From cost-effectiveness ratios to resource allocation: Where to draw the line. In: Sloan FA, editor. Valuing health care: Costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. New York: Cambridge University Press, 1995
15. Eichler H, Kong SX, Gerth WC, et al. Use of cost effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health 2004;7(5):(518)-28
16. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000 20:332-42
17. Black L, Naslund MJ, Gilbert TD, et al. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care 2006;12: S99-110
18. Finasteride. Proscar [package insert]. Whitehouse Station (NJ): Merck & Co., Inc, 2007
19. Dutasteride. Avodart [package insert]. Research Triangle Park (NC): Glaxosmithkline, 2005
20. National Vital Statistics Reports. Deaths: Final data for 2005. Table 5: Number of deaths and death rates by age, and age-adjusted death rates, according to specified Hispanic origin, race for non-Hispanic population, and sex. United States. Natl Vital Stat Rep 2005;56(10)
21. Schroder FH, Roobol MJ, Andriole GL, et al. Defining increased future risk for prostate cancer: Evidence from a population based screening cohort. J Urol 2009;181(1):(69)-74
22. Maattanen J, Bangma CH, Aus G, et al., for the ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009 360:1320-8
23. Schroder FH, Denis LJ, Roobol M, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003 92:1
24. Lefkowitz GK, Taneja SS, Brown J, et al. Follow-up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 2000;168(4 Pt 1):1415-8
25. Postma R, Roobol M, Schroder FH, et al. Lesions predictive for prostate cancer in a screened population: First and second screening round findings. Prostate 2004;61(3):(260)-6
26. Park S, Shinohara K, Grossfeld GD, et al. Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy. J Urol 2001;165(5):(1409)-14
27. Kronz JD, Allan CH, Shaikh AA, et al. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: Data on men with more than one follow-up biopsy. Am J Surg Pathol 2001;25(8):(1079)-85
28. Roobol M, Erasmus MC. Modelling determinants of prostate cancer risk: Analyses of the ERSPC, Section Rotterdam database, version 2.1. Research Triangle Park (NC): Glaxosmithkline, 2006 Oct. 22. (Data on file)
29. National Cancer Data Base. Benchmark reports (v2.0) [online]. Available from URL: Http://Cromwell.facs.org/BMarks/BMPub/Ver10/DxRx/BMPub-DxRx.cfm [Accessed 2009 Jun. 24]
30. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: A population-based survey of urinary symptoms. J Urol 1993 150:85-9
31. Bhatnagar V, Stewart ST, Huynh V, et al. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment. Prostate Cancer Prostatic Dis 2006 9:136-46
32. Nam RK, Toi A, Klotz LH, et al. Assessing individual risk for prostate cancer. J Clin Oncol 2007;25(24):(3582)-8
33. Chun FK, Hutterer GC, Perrotte P, et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU Int 2007 100:37-41
34. Andersen JT, Nickel JC, Marshall VR, et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997 49:839-45
35. Micromedex, Inc. Red book. Vol. 52. Greenwood Village (CO): Micromedex, Inc., 2009
36. American Medical Association. Current procedural terminology CPT 2001. Chicago (IL): Ama Press, 2008
37. Ingenix, Inc. The essential RBRVS: A comprehensive listing of RBRVS values for CPT and HCPCS codes. Eden Prairie (MN): St. Anthony Publishing (Ingenix), 2008
38. Hanks GE, Dunlap K. A comparison of the cost of various treatment methods for early cancer of the prostate. Int J Radiat Oncol Biol Phys 1986;12(10):(1879)-81
39. Litwin MS, Smith RB, Thind A, et al. Cost-efficient radical prostatectomy with a clinical care path. J Urol 1996;155(3):(989)-93
40. Burkhardt JH, Litwin MS, Rose CM, et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J Clin Oncol 2002;20(12):(2869)-75
41. Benoit RM, Cohen JK, Miller Jr RJ. Comparison of the hospital costs for radical prostatectomy and cryosurgical ablation of the prostate. Urology 1998;52(5):(820)-4
42. Koch MO, Smith Jr JA, Hodge EM, et al. Prospective development of a cost-efficient program for radical retropubic prostatectomy. Urology 1994;44(3):(311)-8
43. Silverstein AD, Weizer AZ, Dowell JM, et al. Cost comparison of radical retropubic and radical perineal prostatectomy: Single institution experience. Urology 2004;63(4):(746)-50
44. US Department of Labor, US Bureau of Labor Statistics. US city average, not seasonally adjusted medical care [online]. Available from URL:Uhttp://Data.bls.gov/PDQ/outside. jsp?survey=cu [Accessed 2009 Jun. 24]
45. Coley CM, Barry MJ, Fleming C, et al. Clinical guidelines: Early detection of prostate cancer. Part II. Ann Intern Med 1997;126(6):(468)-79
46. Data on file, GlaxoSmithKline, 2008 Apr. 30
47. Penson DF, Schonfeld WH, Flanders SC, et al. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: Results from the CaPSURE database. Urology 2001 57:499-503
48. Walgreens [online]. Available from URL: Http://Www.walgreens.com [Accessed 2009 Jun. 15]
49. Albertsen PC, Lowe FC, Roehrborn CG. Economic analysis of finasteride: A model-based approach using data from the Proscar long-term efficacy and safety study. Clin Ther 1999;21(6):(1006)-24
50. Mittmann N, Trakas K, Risebrough N, et al. Utility scores for chronic conditions in a community dwelling population. Pharmacoeconomics 1999;15(4):(369)-76
51. Brenmer KE, Chong C, Tomlinson G. A review and metaanalysis of prostate cancer utilities. Med Decis Making 2007 27:288-98
52. Ackerman SJ, Rein AL, Blute M, et al. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: Part I. Methods. Urology 2000 56:972-80
53. Roehrborn CG, McConnell JD, Barry MJ, et al. for the Benign Prostatic Hyperplasia (BPH) Guideline Update Panel of the American Urological Association Education and Research, Inc. Guideline on the management of benign prostatic hyperplasia (BPH), updated 2006 [online]. Available from URL: Http://Www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/ main-reports/bph-management/chapt-4-appendixpdf [Accessed 2009 Jun. 24]
54. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
55. *Stat databases: Incidence-SEER 13 Regs publicuse, November 2004 sub for expanded races (1992-2002), and incidence-SEER 13 Regs excluding AK public-use, November 2004 sub for Hispanics (1992-2002), released April 2005 [online]. Available from URL: Http://Canques. seer.cancer.gov/cgi-bin/cq-submit? dir=seer2002&db=4&rpt= TAB&sel=106211&dec=4&title= Age-specific%20 (Crude) %20SEER%20Incidence%20Rates%20by%20'Expanded'% 20Race-For%20Prostate%20Cancer, %20Males~SEER%2013 %20Registries%20for%201998- 2002&template=faststats&x= Age%20at%20diagnosis2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20&y=Race/ethnicity1, 2, 3, 4 [Accessed 2009 Jun. 24]
56. National Cancer Institute, Statistical Research and Applications Branch. DevCan: Probability of developing or dying of cancer (version 6.1.0), 2006 [online]. Available from URL: Http://Srab.cancer.gov/devcan [Accessed 2009 Jun. 24]
57. National Cancer Institute. Statistical Research and Applications. Surveillance, Epidemiology, and End Results programme. Cancer Query System: Probability of developing or dying of cancer [online]. Available from URL: Http://Srab.cancer.gov/devcan/canques.html [Accessed 2008 Feb. 6]
58. Andriole GL, Pettaway CA, Teloken C, et al. Incidence of biopsy-detectable prostate cancer in the Reduction of Dutasteride of Prostate Cancer Events (REDUCE) trial: Blinded 2-year results [presentation]. Annual Meeting of the American Urological Association; 2009 Apr. 25-30; Chicago (IL)